Synonyms: Examlpe 294 [WO2011112662] | INCB-039110
Compound class:
Synthetic organic
Comment: Itacitinib (INCB039110) is a potent and selective inhibitor of Janus kinase 1 (JAK1). Design and synthesis of this compound is claimed in patent WO2011112662 where it is Example 294 [1].
Ligand Activity Visualisation ChartsThese are box plot that provide a unique visualisation, summarising all the activity data for a ligand taken from ChEMBL and GtoPdb across multiple targets and species. Click on a plot to see the median, interquartile range, low and high data points. A value of zero indicates that no data are available. A separate chart is created for each target, and where possible the algorithm tries to merge ChEMBL and GtoPdb targets by matching them on name and UniProt accession, for each available species. However, please note that inconsistency in naming of targets may lead to data for the same target being reported across multiple charts. ✖ |
|
Immunopharmacology Comments |
Itacitinib (INCB039110) is a potent JAK1 inhibitor that is being evaluated for clinical anti-inflammatory efficacy. |
Immunopharmacology Disease | |||
Disease | X-Refs | Comment | References |
Pruritus | Phase 2 clinical candidate for chronic pruritus (see NCT02909569). | ||
Graft versus host disease | Phase 3 clinical candidate for acute GvHD (see NCT03139604). | ||
Myelofibrosis |
Disease Ontology:
DOID:4971 OMIM: 254450 Orphanet: ORPHA824 |
Phase 2 clinical candidate for myelofibrosis (see NCT03144687). | |
Psoriasis |
Disease Ontology:
DOID:8893 |
Phase 2 study NCT01634087 in psoriasis has been completed. | |
Rheumatoid arthritis |
Disease Ontology:
DOID:7148 OMIM: 180300 |
Phase 2 study NCT01626573 in RA has been completed. |